News & Events
We invite our Clients and Partners to follow the updates on ARS activities, track selected drug and biologic development news, and book a time slot for a meeting at the life science events we go to so that to discuss potential and current projects in person and in detail.
ARS signed an agreement for conducting a number of local bioequivalence studies of generics treating diabetes mellitus type II. ARS is responsible for medical writing, regulatory, clinical and analytical parts as well as final CSR preparation.
We wish our Partners and Colleagues health, prosperity, good fortune, and progress in 2019!
The ARS CRO as well its partnering BE Unit and PK lab have been qualified by the external auditor for conducting series of local bioequivalence clinical trials sponsored by the EU pharmaceutical company.
ARS signed an agreement with the Russian pharmaceutical company on medical writing services, namely clinical study essential documents development for six local bioequivalence clinical research projects.
ARS signed a new agreement with its current Client to conduct a bioequivalence clinical trial for Posaconazole suspension.
ARS signed the agreement to prepare the drug safety update report (DSUR) for submitting to the Federal Service for Surveillance in Healthcare (Roszdravnadzor). The report will be developed by the ARS pharmacovigilance team within the current Phase III gynecology clinical research project sponsored by the leading Russian pharmaceutical company.
ARS conducted a contract with the Russian pharmaceutical company developing generic drugs. The agreement includes ARS assistance with the marketing authorization of the three products in Russia.
ARS made a contract with the pharmaceutical company focused on orphan medicines. The project covers local marketing authorization of the drug treating thrombocytosis.
ARS representatives visited the 4th St. Petersburg International Oncology Forum that is the biggest regional conference in the area. There were interesting and informative discussions and presentations devoted to biosimilars development, oncology clinical research in Russia and local legislation issues within the clinical studies round table held on 08-Jul-2018.
The trends and opportunities in the multinational multicenter clinical trials (MMCT) in Russia are reviewed in the recent article.